BioAge Labs reported that its lead obesity candidate BGE‑102 produced an 86 % median reduction in high‑sensitivity C‑reactive protein (hsCRP) at Day 14 in a multiple‑ascending‑dose cohort of 14 obese participants with elevated inflammation. The cohort received a 120 mg oral dose, and the median baseline hsCRP was 4.85 mg/L, placing participants well above the 2 mg/L threshold associated with lower cardiovascular risk.
In addition to hsCRP, the study documented median reductions of 44 % in interleukin‑6 (IL‑6) and 30 % in fibrinogen, both key markers of systemic inflammation. Ninety‑three percent of participants achieved hsCRP levels below 2 mg/L, a benchmark linked to reduced cardiovascular events. The drug’s pharmacokinetics support once‑daily dosing, and pre‑clinical data suggest brain penetration, positioning BGE‑102 as a potential best‑in‑class oral therapy for metabolic and cardiovascular inflammation.
Safety data were encouraging: no serious adverse events were reported, and the safety profile was consistent with the company’s earlier December 2025 interim data. The absence of dose‑limiting toxicity at 120 mg supports the planned escalation to Phase 2a in the first half of 2026.
From a strategic perspective, these results reinforce BioAge’s focus on aging biology and metabolic disease. BGE‑102’s strong anti‑inflammatory signal, combined with its brain‑penetrant profile, differentiates it from other NLRP3 inhibitors such as Ventyx’s candidate, which achieved a 78 % hsCRP reduction in a similar population. The data also validate the company’s discovery platform that leverages human longevity data, potentially accelerating future candidate development.
CEO John Doe commented, “The 86 % hsCRP reduction and 93 % attainment of <2 mg/L confirm the potency of BGE‑102 and strengthen our confidence in advancing to Phase 2a. These findings underscore the therapeutic promise of targeting NLRP3 to mitigate chronic inflammation in obesity and cardiovascular disease.”
Analysts and investors have responded positively to the data, citing the robust efficacy signals, favorable safety profile, and clear path to Phase 2a as key drivers of optimism. The announcement is expected to enhance BioAge’s competitive positioning in the growing market for metabolic and cardiovascular therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.